Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001312895 | SCV001503366 | uncertain significance | Long QT syndrome | 2025-01-12 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 50 of the KCNJ5 protein (p.Arg50Cys). This variant is present in population databases (rs781011854, gnomAD 0.003%). This missense change has been observed in individual(s) with sudden death (PMID: 26350513). ClinVar contains an entry for this variant (Variation ID: 1014195). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt KCNJ5 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ai |
RCV002224054 | SCV002503247 | uncertain significance | not provided | 2021-12-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002395664 | SCV002698619 | uncertain significance | Cardiovascular phenotype | 2022-01-07 | criteria provided, single submitter | clinical testing | The p.R50C variant (also known as c.148C>T), located in coding exon 1 of the KCNJ5 gene, results from a C to T substitution at nucleotide position 148. The arginine at codon 50 is replaced by cysteine, an amino acid with highly dissimilar properties. This alteration has been reported in a sudden unexplained infant death cohort with limited clinical details (Hertz CL et al. Eur J Hum Genet, 2016 06;24:817-22). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002493633 | SCV002780160 | uncertain significance | Long QT syndrome 13; Familial hyperaldosteronism type III | 2021-10-17 | criteria provided, single submitter | clinical testing |